Warren D. Cooper, Mb, Bs, Bsc, Mfpm
United States of America
Dr. Warren Cooper has served as one of our directors since August 2015 and was appointed lead independent director in November 2015. Dr. Cooper is a UK-trained physician with more than 35 years of experience in the global pharmaceutical industry. Previously, Dr. Cooper was the CEO of Prism Pharmaceuticals, a venture-backed, specialty pharmaceutical company that he led from inception in September 2004 until the sale of the Company to Baxter International in May 2011. His career in the pharmaceutical industry began with Merck, Sharp and Dohme and spanned 12 years, initially as a clinical research physician in the UK, then as head of European and subsequently Worldwide Clinical Research Operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC) in a broad clinical development role, he eventually led that company’s cardiovascular business division, a role with full business lifecycle leadership from in-licensing through development, to P&L responsibility for sales and marketing. Dr. Cooper is a member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. He has previously served on the Boards of Nutrition 21 Inc, Nuron Biotech Inc., Cardiorentis AG and the World Affairs Council of Philadelphia. Dr. Cooper studied at the London Hospital where he earned degrees in Physiology (1974), Medicine and Surgery (1977) granted by the University of London.
At Zynerba Pharmaceuticals, we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs.